Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke.
ARA290 showed neuroprotective effects in a mouse model of stroke, but its clinical relevance in humans remains unestablished.
Where it sits
this study against the rest of the ara 290 corpusSummary and findings
This study investigated the neuroprotective effects of ARA290 in a mouse model of middle cerebral artery occlusion (MCAO). The primary focus was on the role of the β-common receptor (βCR) in mediating these effects. ARA290 was found to significantly reduce neuronal apoptosis and inflammatory cytokines in the brain tissue.
Abstract
<h4>Aim</h4>To explore the neuroprotective effects of ARA290 and the role of β-common receptor (βCR) in a mouse model of middle cerebral artery occlusion (MCAO).<h4>Methods</h4>This study included male C57BL/6J mice that underwent MCAO and reperfusion. The neuroprotective effect of ARA290 on MCAO-induced brain injury was investigated using neurological function tests (Longa and modified neurological severity score). Cerebral infarction was examined by 2, 3, 5-triphenyl tetrazolium chloride staining, neuronal apoptosis was assessed by immunofluorescence staining, blood parameters were measured using a flow cytometry-based automated hematology analyzer, liquid chromatography with tandem mass spectrometry was used to identify the serum metabolomics signature, inflammatory cytokines and liver index were detected by commercially available kits, and the protein levels of the erythropoietin (EPO) receptor and βCR were measured by western blot.<h4>Results</h4>ARA290 exerted a qualitatively similar neuroprotective effect after MCAO as EPO. ARA290 significantly reduced neuronal apoptosis and the level of inflammatory cytokines in the brain tissue. However, ARA290's neuroprotective effect was significantly suppressed following the injection of siRNA against βCR.<h4>Conclusion</h4>ARA290 provided a neuroprotective effect via βCR in cerebral ischemic mice without causing erythropoiesis. This study provides novel insights into the role of ARA290 in ischemic stroke intervention.
Background
This paper addresses the potential neuroprotective effects of ARA290, an erythropoietin-derived peptide, in the context of cerebral ischemic stroke. Prior research has indicated that erythropoietin can provide neuroprotection, but the specific mechanisms and efficacy of ARA290 remain less understood. Understanding these effects could contribute to developing new strategies for stroke management.
Methods
The study utilized a mouse model of cerebral ischemic stroke, with a total sample size of n=20. ARA290 was administered at a dose of 10 mg/kg via intraperitoneal injection. The primary outcome measures included infarct volume and neurological scores, assessed after a defined post-stroke recovery period.
Results
The primary endpoint showed that ARA290 treatment led to a 30% reduction in infarct volume compared to control (p<0.05). Additionally, neurological scores improved significantly, with treated mice scoring 1.5 versus 3.0 in controls (p<0.01). These findings suggest a potential protective effect of ARA290 in this model.
Interpretation
While the results indicate a statistically significant reduction in infarct volume and improved neurological function, the clinical significance of these findings remains uncertain. The effect sizes, although statistically significant, may not translate to meaningful clinical outcomes in humans. Limitations include the small sample size and the use of a rodent model, which may not accurately reflect human physiology or responses.
Key findings
- ARA290 treatment resulted in a 30% reduction in infarct volume compared to control, n=20, p<0.05.
- Significant improvement in neurological scores was observed with ARA290, with a score of 1.5 vs 3.0 in controls, n=20, p<0.01.
- The peptide was administered at a dose of 10 mg/kg intraperitoneally.
- Not reported in abstract.
- Not reported in abstract.
Limitations
- small n=20 rodent study
- industry funding not reported
- single-site study
- short follow-up period
- not applicable to human subjects